Abstract
In 1912, S. A. Kinnear Wilson described hepatolenticular degeneration, which was later named “Wilson’s disease.” This autosomal recessive disease results in the deposition of excess copper in the body, especially in the brain and liver. Although our understanding of the clinical findings, laboratory abnormalities, molecular aspects, and treatment strategies is sophisticated, we still do not fully understand the pathogenesis of this fascinating disease. Inevitably fatal at the time of its description, Wilson’ s disease is now one of the most treatable hereditary neurologic disorders. Because it has a wide clinical spectrum and can be treated, Wilson’s disease should be considered in the differential diagnostic evaluation of patients seen by neurologists, psychiatrists, gastroenterologists, and other physicians.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Selected Reading
Biglan AW, Taylor SL. Kayser-Fleischer ring in a patient with Wilson’s disease. N Engl J Med 1993; 328: 1820.
Bowcock AM, Farrer LA, Cavalli-Sforza LL, Hebert JM, Kidd KK, Frydman M, Bonne-Tamir B. Mapping the Wilson disease locus to a cluster of linked polymorphic markers on chromosome 13. Am JHum Genet 1987; 41: 27–35.
Brewer GJ. Practical recommendations and new therapies for Wilson’s disease. Drugs 1995; 50: 240–249. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine (Baltimore) 1992; 71: 139–164.
Cartwright GE. Diagnosis of treatable Wilson’s disease. N Engl J Med 1978; 298: 1347–1350.
Farrer LA, Bowcock AM, Hebert JM, Bonne-Tamir B, Sternlieb I, Giagheddu M, St George-Hyslop P
Frydman M, Lossner J, Demelia L, Carcassi C, Lee R, Beker R, Bale AE, Donis-Keller H, Scheinberg
IH, Cavalli-Sforza LL. Predictive testing for Wilson’s disease using tightly linked and flanking DNA markers. Neurology 1991; 41: 992–999.
Marsden CD. Wilson’s disease. Q J Med 1987; 65: 959–966.
Rathbun JK. Neuropsychological aspects of Wilson’s disease. Int J Neurosci 1996; 85: 221–229.
Saatci I, Topcu M, Baltaoglu FF, Kose G, Yalaz K, Renda Y, Besim A. Cranial MR findings in Wilson’s disease. Acta Radiol 1997; 38: 250–258.
Shah AB, Chernov I, Zhang HT, Ross BM, Das K, Lutsenko S, Parano E, Pavone L, Evgrafov O, IvanovaSmolenskaya IA, Anneren G, Westermark K, Urrutia FH, Penchaszadeh GK, Sternlieb I, Scheinberg IH, Gilliam TC, Petrukhin K. Identification and analysis of mutations in the Wilson disease gene (ATP7B): population frequencies, genotype-phenotype correlation, and functional analyses. Am J Hum Genet 1997; 61: 317–328.
Starosta-Rubinstein S. Treatment of Wilson’ s disease, in Treatment of Movement Disorders ( Kurlan R ed), JB Lippincott, Philadelphia, 1995, pp. 115–151.
Strickland GT, Beckner WM, Leu ML. Absorption of copper in homozygotes and heterozygotes for Wilson’ s disease and controls: isotope tracer studies with 67Cu and 64Cu. Clin Sci 1972; 43: 617–625.
Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995; 9: 210–217.
Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Lancet 1912; 1: 1115–1119.
Yarze JC, Martin P, Munoz SJ, Friedman LS. Wilson’s disease: current status. Am JMed 1992; 92: 643–654.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gwinn-Hardy, K.A. (2000). Wilson’s Disease. In: Adler, C.H., Ahlskog, J.E. (eds) Parkinson’s Disease and Movement Disorders. Current Clinical Practice. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-410-8_32
Download citation
DOI: https://doi.org/10.1007/978-1-59259-410-8_32
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-095-3
Online ISBN: 978-1-59259-410-8
eBook Packages: Springer Book Archive